Two major U.S. medical organizations have issued new guidelines recommending hormone replacement therapy (HRT) as a first-line treatment for hot flashes and night sweats, marking a significant shift from the caution that dominated menopause care for more than two decades.
The American College of Obstetricians and Gynecologists (ACOG) released updated guidelines in 2026 that recommend HRT for vasomotor symptoms — the medical term for hot flashes and night sweats — according to Penn State Health. The American College of Physicians (ACP) followed in October 2026 with its own endorsement of hormone therapy as a first-line option for the same symptoms.
The new guidance represents a reversal from the position many physicians adopted after the Women's Health Initiative published findings in 2002 linking estrogen-plus-progestin therapy to increased risks of breast cancer, cardiovascular disease, stroke and pulmonary embolism. Those findings led to black box warnings on hormone therapy products and caused a sharp decline in HRT use, with many doctors turning to nonhormonal treatments instead.
But researchers continued studying the risks and benefits, particularly how a patient's age and the timing of treatment affect outcomes. In November 2025, after reviewing more recent research, the U.S. Food and Drug Administration requested that drug manufacturers remove references to cardiovascular disease, breast cancer and probable dementia from the boxed warnings on menopausal hormone therapy products. The FDA approved updated labeling for the first products in February 2026, Penn State Health reported. A boxed warning about endometrial cancer remains for systemic estrogen-only products.
Dr. Cynthia Chuang, a women's health and internal medicine physician at Penn State Health Cocoa Outpatient Center and director of the health system's Menopause Clinic, told Penn State Health that the ACOG guidelines are a major step forward.
"They did a comprehensive review of the research and literature around vasomotor symptoms and sleep disturbances related to vasomotor symptoms," Chuang said. "This really elevates it and says that unless you have risk factors that don't allow you to take hormone therapy for some reason, they recommend systemic menopausal hormone therapy."
Chuang said the dual endorsements from ACOG and ACP mean more physicians — not just specialists — will be equipped to help patients experiencing hot flashes.
"The American College of Obstetricians and Gynecologists statement tells OB-GYNs that hormone replacement therapy is part of their standard of care," she said. "The American College of Physicians statement is telling internists the same thing. This is part of what we do."
Typically, patients who use HRT begin before age 60 or within 10 years of the start of spontaneous menopause, according to the guidelines. The organizations emphasize working with patients to determine when to start and stop therapy and whether the benefits outweigh the risks.
HRT is not the only option. The updated guidelines also recommend several nonhormonal alternatives, including certain antidepressants, neurokinin receptor antagonists such as fezolinetant and elinzanetant (marketed as Veozah and Lynkuet in the U.S.), and nonpharmacological treatments like meditation, cognitive behavioral therapy, acupuncture and hypnosis.
Chuang noted that the new guidelines address only vasomotor symptoms. Research has not yet produced conclusive evidence to support recommending HRT for other menopausal symptoms such as mood disorders.
For students and younger adults, the shift matters because it affects how future physicians are trained and how menopause care will be delivered to a generation that is now in or approaching medical school. Medical students and residents will learn a different standard of care than their predecessors did, and the change may also influence how primary care doctors — including those at campus health centers — approach conversations about menopause with patients.
The new guidelines also carry a warning about unregulated supplements. The Menopause Society, ACOG and ACP all caution that herbal supplements marketed for menopause symptoms lack clinical evidence to support their use, according to Penn State Health.
"Many women come to me when they're already on supplements. I'm not here to say they are doing something wrong, and they can still choose to take them," Chuang said. "But I do tell them that there's no evidence that they are beneficial, and to be wary of influencers, including healthcare providers, selling supplements for their own financial gain."
One patient, Rebecca G. of Elizabethtown, Pennsylvania, told Penn State Health that her primary care physician was not familiar with HRT or comfortable prescribing it for her menopause symptoms. A co-worker recommended the Penn State Health Menopause Clinic, where Chuang prescribed an estrogen patch. Within weeks, Rebecca noticed fewer hot flashes and has now been using the patches for a year with annual check-ins to ensure the treatment remains appropriate.
Chuang said having evidence-based options is especially important in the age of social media, where menopause-related marketing has increased significantly.
"Many menopause supplements on the market now can also be expensive and are promoted by prominent physicians in the menopause sphere," she said. "I urge patients to follow the science, not the hype."